FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.
Lenzer
Jeanne
J
D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D008565:Membrane Proteins; D009203:Myocardial Infarction / Q000139:chemically induced*; D011451:Prostaglandin-Endoperoxide Synthases; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced*; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases